Infectious diseases

Severe sepsis / septic shock – AB103 peptide is in advanced pre-clinical R&D, has yielded encouraging results in sepsis models: superantigen lethality, Gram-positive and Gram-negative sepsis models. GMP production of AB103 was finalized and it is now in GLP Tox/PK studies.

Toxic shock (Biodefense) - AB103 peptide is in advanced pre-clinical R&D, has demonstrated the ability to protect and rescue of mice from lethal toxic shock and protect pigs from intoxication in a quantitative model of incapacitation.

Autoimmune diseases

Immunomodulator leads are in pre-clinical studies in accepted animal models of autoimmune disease, with encouraging results in vivo.